Acadia and Saniona Successfully Complete Phase 1 MAD Study of ACP-711

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) have successfully completed two planned cohorts in their Phase 1 multiple-ascending-dose (MAD) study of ACP-711, formerly known as SAN711, in healthy volunteers. The investigational therapy was safe and well tolerated, with no serious adverse events reported. Most adverse effects were mild, and participants completed the study without safety concerns related to laboratory results, cardiovascular health, or neurological function.

Following these promising results, Acadia and Saniona are pursuing regulatory approval to expand the study to elderly healthy volunteers and test higher repeated doses. While awaiting approval, the trial has been temporarily paused. ACP-711 is being developed as a potential treatment for essential tremor, reinforcing Acadia's commitment to advancing neuroscience breakthroughs for neuro-rare diseases.